Pacira BioSciences (PCRX) Non-Current Assets (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Non-Current Assets of $693.6 million for Q1 2026, down 16.1% year-over-year from $826.7 million in Q1 2025, and down 3.26% quarter-over-quarter from $716.9 million in Q4 2025.
Pacira BioSciences (PCRX) Non-Current Assets (2010 - 2026) Analysis & Trends
Pacira BioSciences' Non-Current Assets history runs 17 years deep, the most recent figure standing at $693.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 16.1% year-over-year to $693.6 million; the TTM figure through Mar 2026 stood at $2.9 billion (down 15.64% YoY), while the FY2025 annual figure was $716.9 million, down 11.31% from the prior year.
- Non-Current Assets for Q1 2026 stood at $693.6 million, down from $716.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $1.2 billion in Q1 2022, with the low at $693.6 million in Q1 2026.
- The 5-year median for Non-Current Assets is $1.0 billion (2024), against an average of $981.6 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 126.49% in 2022, then decreased 24.05% in 2024.
- Pacira BioSciences' Non-Current Assets stood at $1.2 billion in 2022, then decreased by 10.02% to $1.1 billion in 2023, then dropped by 24.05% to $808.4 million in 2024, then decreased by 11.31% to $716.9 million in 2025, then decreased by 3.26% to $693.6 million in 2026.
- Business Quant data shows PCRX's Non-Current Assets at $693.6 million in Q1 2026, $716.9 million in Q4 2025, and $734.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Pacira BioSciences | 939.59 Mn | 688.56 Mn | 148.24 Mn | 628.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 628.76 Mn |
| Mar 31, 2026 | 693.57 Mn |
| Dec 31, 2025 | 716.94 Mn |
| Sep 30, 2025 | 734.83 Mn |
| Jun 30, 2025 | 791.65 Mn |
| Mar 31, 2025 | 826.71 Mn |
| Dec 31, 2024 | 808.39 Mn |
| Sep 30, 2024 | 831.72 Mn |
| Jun 30, 2024 | 1.01 Bn |
| Mar 31, 2024 | 1.04 Bn |
| Dec 31, 2023 | 1.06 Bn |
| Sep 30, 2023 | 1.09 Bn |
| Jun 30, 2023 | 1.11 Bn |
| Mar 31, 2023 | 1.15 Bn |
| Dec 31, 2022 | 1.18 Bn |
| Sep 30, 2022 | 1.20 Bn |
| Jun 30, 2022 | 1.21 Bn |
| Mar 31, 2022 | 1.22 Bn |
| Dec 31, 2021 | 1.21 Bn |
| Sep 30, 2021 | 533.65 Mn |